Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]
Awaiting development
Reference number: GID-TA11773
Expected publication date: TBC
To appraise the clinical and cost effectiveness of Everolimus + Giredestrant within its marketing authorisation for treating breast
cancer